Controlled Substances: Proposed Adjustment to the Aggregate Production Quotas for 2012, 39737-39741 [2012-16396]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices
San Rafael, California; Canadian Solar
Inc. of Kitchener, Ontario, Canada; and
Canadian Solar (USA) Inc. of San
Ramon, California. Id.
On May 25, 2012, all of the private
parties filed a joint motion to terminate
the investigation based on confidential
settlement agreements under
Commission rules 210.21(a)(2) and (b).
The Commission investigative attorney
supported the motion.
On June 13, 2012, the presiding ALJ
issued an ID (Order No. 11) granting the
joint motion. No party petitioned for
review of the ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, and in section
210.42(h) of the Commission’s Rules of
Practice and Procedure, 19 CFR
210.42(h).
By order of the Commission.
Issued: June 29, 2012.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2012–16433 Filed 7–3–12; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
TKELLEY on DSK3SPTVN1PROD with NOTICES
Notice of Lodging of Proposed
Consent Decree With Dairyland Power
Cooperative Under the Clean Air Act
Pursuant to 28 CFR 50.7, notice is
hereby given that on June 28, 2012, a
proposed Consent Decree in United
States of America v. Dairyland Power
Cooperative (‘‘Dairyland’’), Civil Action
No. 12-cv-462, was lodged with the
United States District Court for the
Western District of Wisconsin.
In this civil enforcement action under
the federal Clean Air Act (‘‘Act’’), the
United States alleges that Dairyland—an
electric utility—failed to comply with
certain requirements of the Act intended
to protect air quality. The complaint
alleges that Dairyland violated the
Prevention of Significant Deterioration
(‘‘PSD’’) and Title V provisions of the
Act, 42 U.S.C. 7401–7671 et seq., and
related state and federal implementing
regulations, at the Alma/J.P. Madgett
Generating Station, a coal-fired power
plant in Buffalo County, Wisconsin, and
the Genoa Generating Station, a coalfired power plant in Vernon County,
Wisconsin. The alleged violations arise
from the construction of modifications
at the power plants and operation of the
plants in violation of PSD and Title V
requirements. The complaint alleges
that Dairyland failed to obtain
appropriate permits and failed to install
and apply required pollution control
VerDate Mar<15>2010
16:48 Jul 03, 2012
Jkt 226001
devices to reduce emissions of various
air pollutants. The complaint seeks both
injunctive relief and civil penalties.
The proposed Decree lodged with the
Court requires installation and
operation of certain pollution control
devices at the Alma/J.P. Madgett and
Genoa plants, and the permanent
cessation of operations of certain units
at the Alma/J.P. Madgett plant. The
settlement will reduce emissions of
sulfur dioxide (‘‘SO2’’), nitrogen oxides
(‘‘NOX’’), and particular matter (‘‘PM’’)
through emission control requirements
and limitations specified by the
proposed Decree. Dairyland will also
fund environmental projects at a cost of
at least $5 million to mitigate the
alleged adverse effects of its past
violations, and will pay a civil penalty
of $950,000.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either emailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. Dairyland Power Cooperative,
D.J. Ref. 90–5–2–1–10163.
During the public comment period,
the Consent Decree may also be
examined on the following Department
of Justice Web site, https://
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611 or
by faxing or emailing a request to
‘‘Consent Decree Copy’’
(EESCDCopy.ENRD@usdoj.gov), fax no.
(202) 514–0097, phone confirmation
number (202) 514–5271. If requesting a
copy from the Consent Decree Library
by mail, please enclose a check in the
amount of $24.25 (25 cents per page
reproduction cost) payable to the U.S.
Treasury or, if requesting by email or
fax, forward a check in that amount to
the Consent Decree Library at the
address given above.
Maureen Katz,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 2012–16353 Filed 7–3–12; 8:45 am]
BILLING CODE 4410–15–P
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
39737
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–363]
Controlled Substances: Proposed
Adjustment to the Aggregate
Production Quotas for 2012
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice with request for
comments.
AGENCY:
This notice proposes to adjust
the 2012 aggregate production quotas for
several controlled substances in
schedules I and II of the Controlled
Substances Act (CSA).
DATES: Electronic comments must be
submitted and written comments must
be postmarked on or before August 6,
2012. Commenters should be aware that
the electronic Federal Docket
Management System will not accept
comments after midnight Eastern Time
on the last day of the comment period.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–363’’ on all electronic and
written correspondence. DEA
encourages all comments be submitted
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at the
https://www.regulations.gov Web site for
easy reference. Paper comments that
duplicate the electronic submission are
not necessary as all comments
submitted to www.regulations.gov will
be posted for public review and are part
of the official docket record. Should
you, however, wish to submit written
comments via regular or express mail,
they should be sent to the Drug
Enforcement Administration, Attention:
DEA Federal Register Representative/
ODL, 8701 Morrissette Drive,
Springfield, VA 22152.
FOR FURTHER INFORMATION CONTACT: John
W. Partridge, Chief, Liaison and Policy
Section, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152, Telephone: (202)
307–4654.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Posting of Public Comments
Please note that all comments
received are considered part of the
public record and made available for
public inspection online at https://
www.regulations.gov and in the DEA’s
public docket. Such information
includes personal identifying
E:\FR\FM\05JYN1.SGM
05JYN1
39738
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want posted online or made
available in the public docket in the first
paragraph of your comment and identify
what information you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment. If a comment has
so much confidential business
information that it cannot be effectively
redacted, all or part of that comment
may not be posted online or made
available in the public docket.
Personal identifying information and
confidential business information
identified and located as set forth above
will be redacted, and the comment, in
redacted form, will be posted online and
placed in the DEA’s public docket file.
Please note that the Freedom of
Information Act applies to all comments
received. If you wish to inspect the
agency’s public docket file in person by
appointment, please see the FOR
FURTHER INFORMATION CONTACT
paragraph.
Background
Section 306 of the CSA (21 U.S.C.
826) requires that the Attorney General
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II.
This responsibility has been delegated
to the Administrator of the DEA by 28
CFR 0.100. The Administrator, in turn,
has redelegated this function to the
Deputy Administrator, pursuant to 28
CFR 0.104. The 2012 established
aggregate production quotas for
controlled substances in schedules I and
II were published in the Federal
Register (76 FR 78044) on December 15,
2011. That notice stipulated that, as
provided for in 21 CFR 1303.13, all
aggregate production quotas are subject
to adjustment.
Analysis for Proposed Revised 2012
Aggregate Production Quotas
DEA now proposes to adjust the
established 2012 aggregate production
quotas for some schedule I and II
controlled substances. In proposing the
adjustment, DEA has taken into account
the criteria that DEA is required to
consider in accordance with 21 CFR
1303.13. DEA proposes the adjustment
of the aggregate production quotas for
basic classes of schedule I and II
controlled substances by considering (1)
Changes in demand for the class,
changes in the national rate of net
disposal for the class, and changes in
the rate of net disposal by the registrants
holding individual manufacturing
quotas for the class; (2) whether any
increased demand or changes in the
national and/or individual rates of net
disposal are temporary, short term, or
long term; (3) whether any increased
demand can be met through existing
inventories, increased individual
manufacturing quotas, or increased
importation without increasing the
aggregate production quota; (4) whether
any decreased demand will result in
excessive inventory accumulation by all
persons registered to handle the class;
and (5) other factors affecting the
medical, scientific, research, and
industrial needs of the United States
and lawful export requirements, as the
Administrator finds relevant.
In determining whether to propose
adjustments to the 2012 aggregate
production quotas, DEA considered
updated information obtained from
2011 year-end inventories, 2011
disposition data submitted by quota
applicants, estimates of the medical
needs of the United States, product
development, and other information
made available to DEA after the initial
aggregate production quotas had been
established. The Deputy Administrator,
therefore, proposes to adjust the 2012
aggregate production quotas for some
schedule I and II controlled substances,
expressed in grams of anhydrous acid or
base, as follows:
Previously
established
2012 quotas
Basic class
Proposed
adjusted 2012
quotas
TKELLEY on DSK3SPTVN1PROD with NOTICES
Schedule I
1-[1-(2-Thienyl)cyclohexyl]piperidine .................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) .............................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073) ..........................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .........................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH-018) ........................................................................................................
2,5-Dimethoxyamphetamine ..............................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ....................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ...................................................................................................
3-Methylfentanyl .................................................................................................................................................
3-Methylthiofentanyl ...........................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ..........................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ...........................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) ...............................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .........................................................................................................
3,4,5-Trimethoxyamphetamine ..........................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ....................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ................................................................................................
4-Methoxyamphetamine ....................................................................................................................................
4-Methylaminorex ..............................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ....................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ......................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .......................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .........................................................................
VerDate Mar<15>2010
16:48 Jul 03, 2012
Jkt 226001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
E:\FR\FM\05JYN1.SGM
0 g ....................
45 g ..................
45 g ..................
2 g ....................
45 g ..................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
22 g ..................
8 g ....................
15 g ..................
22 g ..................
8 g ....................
2 g ....................
2 g ....................
2 g ....................
77 g ..................
2 g ....................
2 g ....................
8 g ....................
68 g ..................
53 g ..................
05JYN1
5 g.
No Change.
No Change.
No Change.
No Change.
12 g.
12 g.
12 g.
No Change.
No Change.
30 g.
12 g.
24 g.
30 g.
12 g.
12 g.
12 g.
12 g.
88 g.
12 g.
12 g.
12 g.
No Change.
No Change.
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices
39739
Basic class
Previously
established
2012 quotas
Proposed
adjusted 2012
quotas
5-Methoxy-3,4-methylenedioxyamphetamine ....................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................
Acetyl-alpha-methylfentanyl ...............................................................................................................................
Acetyldihydrocodeine .........................................................................................................................................
Acetylmethadol ..................................................................................................................................................
Allylprodine ........................................................................................................................................................
Alphacetylmethadol ............................................................................................................................................
Alpha-ethyltryptamine ........................................................................................................................................
Alphameprodine .................................................................................................................................................
Alphamethadol ...................................................................................................................................................
Alpha-methylfentanyl .........................................................................................................................................
Alpha-methylthiofentanyl ....................................................................................................................................
Alpha-methyltryptamine (AMT) ..........................................................................................................................
Aminorex ............................................................................................................................................................
Benzylmorphine .................................................................................................................................................
Betacetylmethadol .............................................................................................................................................
Beta-hydroxy-3-methylfentanyl ..........................................................................................................................
Beta-hydroxyfentanyl .........................................................................................................................................
Betameprodine ...................................................................................................................................................
Betamethadol .....................................................................................................................................................
Betaprodine ........................................................................................................................................................
Bufotenine ..........................................................................................................................................................
Cathinone ...........................................................................................................................................................
Codeine-N-oxide ................................................................................................................................................
Diethyltryptamine ...............................................................................................................................................
Difenoxin ............................................................................................................................................................
Dihydromorphine ................................................................................................................................................
Dimethyltryptamine ............................................................................................................................................
Gamma-hydroxybutyric acid ..............................................................................................................................
Heroin ................................................................................................................................................................
Hydromorphinol ..................................................................................................................................................
Hydroxypethidine ...............................................................................................................................................
Ibogaine .............................................................................................................................................................
Lysergic acid diethylamide (LSD) ......................................................................................................................
Marihuana ..........................................................................................................................................................
Mescaline ...........................................................................................................................................................
Methaqualone ....................................................................................................................................................
Methcathinone ...................................................................................................................................................
Methyldihydromorphine ......................................................................................................................................
Morphine-N-oxide ..............................................................................................................................................
N-Benzylpiperazine ............................................................................................................................................
N,N-Dimethylamphetamine ................................................................................................................................
N-Ethylamphetamine .........................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ....................................................................................................
Noracymethadol .................................................................................................................................................
Norlevorphanol ...................................................................................................................................................
Normethadone ...................................................................................................................................................
Normorphine ......................................................................................................................................................
Para-fluorofentanyl .............................................................................................................................................
Phenomorphan ..................................................................................................................................................
Pholcodine .........................................................................................................................................................
Properidine .........................................................................................................................................................
Psilocybin ...........................................................................................................................................................
Psilocyn ..............................................................................................................................................................
Tetrahydrocannabinols ......................................................................................................................................
Thiofentanyl .......................................................................................................................................................
Tilidine ................................................................................................................................................................
Trimeperidine .....................................................................................................................................................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
3 g ....................
4 g ....................
602 g ................
2 g ....................
50 g ..................
3,608,000 g ......
7 g ....................
47,000,000 g ....
20 g ..................
54 g ..................
2 g ....................
5 g ....................
16 g ..................
21,000 g ...........
5 g ....................
10 g ..................
4 g ....................
2 g ....................
655 g ................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
52 g ..................
2 g ....................
18 g ..................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
2 g ....................
393,000 g .........
2 g ....................
10 g ..................
2 g ....................
12 g.
12 g.
No Change.
No Change.
No Change.
No Change.
No Change.
12 g.
No Change.
No Change.
No Change.
No Change.
12 g.
12 g.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
12 g.
No Change.
12 g.
No Change.
No Change.
18 g.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
13 g.
No Change.
12 g.
No Change.
No Change.
12 g.
12 g.
12 g.
12 g.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
2 g ....................
2 g ....................
1,800,000 g ......
15,000 g ...........
2 g ....................
40,007 g ...........
8,500,000 g.
25,300,000 g ....
No Change.
27 g.
No Change.
19,550 g.
No Change.
No Change.
TKELLEY on DSK3SPTVN1PROD with NOTICES
Schedule II
1-Phenylcyclohexylamine ..................................................................................................................................
1-Piperdinocyclohexanecarbonitrile ...................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .......................................................................................................
Alfentanil ............................................................................................................................................................
Alphaprodine ......................................................................................................................................................
Amobarbital ........................................................................................................................................................
Amphetamine (for conversion) ..........................................................................................................................
Amphetamine (for sale) * ...................................................................................................................................
VerDate Mar<15>2010
16:48 Jul 03, 2012
Jkt 226001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\05JYN1.SGM
05JYN1
33,400,000 g.
39740
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices
Previously
established
2012 quotas
Basic class
Proposed
adjusted 2012
quotas
* DEA has determined that the revised total quantity to provide for the estimated medical, scientific, research, and industrial needs of the United
States, lawful export requirements, and the establishment and maintenance of reserve stock is 29,400,000 g. DEA has further determined
that an additional 4,000,000 g is necessary to provide for future research and development needs and unexpected emergencies that could
affect market availability.
Carfentanil ..........................................................................................................................................................
Cocaine ..............................................................................................................................................................
Codeine (for conversion) ...................................................................................................................................
Codeine (for sale) ..............................................................................................................................................
Dextropropoxyphene ..........................................................................................................................................
Dihydrocodeine ..................................................................................................................................................
Diphenoxylate ....................................................................................................................................................
Ecgonine ............................................................................................................................................................
Ethylmorphine ....................................................................................................................................................
Fentanyl .............................................................................................................................................................
Glutethimide .......................................................................................................................................................
Hydrocodone (for sale) ......................................................................................................................................
Hydromorphone .................................................................................................................................................
Isomethadone ....................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ......................................................................................................................
Levomethorphan ................................................................................................................................................
Levorphanol .......................................................................................................................................................
Lisdexamfetamine ..............................................................................................................................................
Meperidine .........................................................................................................................................................
Meperidine Intermediate-A ................................................................................................................................
Meperidine Intermediate-B ................................................................................................................................
Meperidine Intermediate-C ................................................................................................................................
Metazocine .........................................................................................................................................................
Methadone (for sale) .........................................................................................................................................
Methadone Intermediate ....................................................................................................................................
Methamphetamine .............................................................................................................................................
0 g ....................
216,000 g .........
65,000,000 g ....
39,605,000 g ....
7 g ....................
400,000 g .........
900,000 g .........
83,000 g ...........
2 g ....................
1,428,000 g ......
2 g ....................
59,000,000 g ....
3,455,000 g ......
4 g ....................
3 g ....................
5 g ....................
3,600 g .............
12,000,000 g ....
5,500,000 g ......
5 g ....................
9 g ....................
5 g ....................
5 g ....................
20,000,000 g ....
26,000,000 g ....
3,130,000 g ......
5 g.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
63,000,000 g.
3,628,000 g.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)]
TKELLEY on DSK3SPTVN1PROD with NOTICES
Methylphenidate .................................................................................................................................................
Morphine (for conversion) ..................................................................................................................................
Morphine (for sale) ............................................................................................................................................
Nabilone .............................................................................................................................................................
Noroxymorphone (for conversion) .....................................................................................................................
Noroxymorphone (for sale) ................................................................................................................................
Opium (powder) .................................................................................................................................................
Opium (tincture) .................................................................................................................................................
Oripavine ............................................................................................................................................................
Oxycodone (for conversion) ..............................................................................................................................
Oxycodone (for sale) .........................................................................................................................................
Oxymorphone (for conversion) ..........................................................................................................................
Oxymorphone (for sale) .....................................................................................................................................
Pentobarbital ......................................................................................................................................................
Phenazocine ......................................................................................................................................................
Phencyclidine .....................................................................................................................................................
Phenmetrazine ...................................................................................................................................................
Phenylacetone ...................................................................................................................................................
Racemethorphan ...............................................................................................................................................
Remifentanil .......................................................................................................................................................
Secobarbital .......................................................................................................................................................
Sufentanil ...........................................................................................................................................................
Tapentadol .........................................................................................................................................................
Thebaine ............................................................................................................................................................
Aggregate production quotas for all
other schedule I and II controlled
substances included in 21 CFR 1308.11
and 1308.12 remain at zero. Pursuant to
21 CFR part 1303, the Deputy
Administrator may adjust the 2012
aggregate production quotas and
individual manufacturing quotas
allocated for the year.
VerDate Mar<15>2010
16:48 Jul 03, 2012
Jkt 226001
Comments
Pursuant to 21 CFR 1303.11 and
1303.13, any interested person may
submit written comments on or
objections to these proposed
determinations. Based on comments
received in response to this Notice, the
Deputy Administrator may hold a
public hearing on one or more issues
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
56,000,000 g ....
83,000,000 g ....
39,000,000 g ....
20,502 g ...........
7,200,000 g ......
401,000 g .........
63,000 g ...........
1,000,000 g ......
9,800,000 g ......
5,600,000 g ......
98,000,000 g ....
12,800,000 g ....
5,500,000 g ......
34,000,000 g ....
5 g ....................
24 g ..................
2 g ....................
16,000,000 g ....
2 g ....................
2,500 g .............
336,002 g .........
5,000 g .............
5,400,000 g ......
116,000,000 g ..
No Change.
No Change.
No Change.
No Change.
No Change.
1,981,000 g.
73,000 g.
No Change.
15,300,000 g.
No Change.
98,700,000 g.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
No Change.
raised. In the event the Deputy
Administrator decides in his sole
discretion to hold such a hearing, the
Deputy Administrator will publish a
notice of any such hearing in the
Federal Register. After consideration of
any comments and after a hearing, if one
is held, the Deputy Administrator will
publish in the Federal Register a Final
E:\FR\FM\05JYN1.SGM
05JYN1
Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices
Order determining any adjustment of
the aggregate production quota.
Dated: June 28, 2012.
Michele M. Leonhart,
Administrator.
[FR Doc. 2012–16396 Filed 7–3–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Myoderm
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on May 9, 2012, Myoderm, 48 East
Main Street, Norristown, Pennsylvania
19401, made application to the Drug
Enforcement Administration (DEA) for
registration as an importer of the
following basic classes of controlled
substances:
Drug
Schedule
TKELLEY on DSK3SPTVN1PROD with NOTICES
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Nabilone (7379) ............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Dated: June 28, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–16493 Filed 7–3–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
National Institute of Corrections
The company plans to import the
listed controlled substances in finished
dosage form for clinical trials, and
research.
The import of the above listed basic
classes of controlled substances would
be granted only for analytical testing
and clinical trials. This authorization
does not extend to the import of a
finished FDA approved or nonapproved dosage form for commercial
distribution in the United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C.
952(a)(2)(B) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
VerDate Mar<15>2010
16:48 Jul 03, 2012
Jkt 226001
to 21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 6, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in
21 CFR 1301.34(b), (c), (d), (e), and (f).
As noted in a previous notice published
in the Federal Register on September
23, 1975, 40 FR 43745–46, all applicants
for registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Solicitation for a Cooperative
Agreement—Curricula Review and
Revision: NIC Trainer Development
Series
National Institute of
Corrections, U.S. Department of Justice.
ACTION: Solicitation for a Cooperative
Agreement.
AGENCY:
The National Institute of
Corrections’ (NIC) Academy Division is
soliciting proposals from organizations,
groups, or individuals to enter into a
cooperative agreement for the review,
revision, and/or development of
competency-based, blended modality
training curricula with the aim of
providing corrections agencies and
professionals with the knowledge,
skills, and abilities needed to train and
develop their staff.
DATES: Application must be received by
4 p.m. (EDT) on Friday, July 20, 2012.
ADDRESSES: Mailed applications must be
sent to: Director, National Institute of
Corrections, 320 First Street NW., Room
5002, Washington, DC 20534.
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
39741
Applicants are encouraged to use
Federal Express, UPS, or similar service
to ensure delivery by the due date.
Hand delivered applications should
be brought to 500 First Street NW.,
Washington, DC 20534. At the front
desk, dial 7–3106, extension 0 for
pickup.
Faxed applications will not be
accepted. Electronic applications can be
submitted via https://www.grants.gov.
FOR FURTHER INFORMATION CONTACT: All
technical or programmatic questions
concerning this announcement should
be directed to Michael Guevara,
Correctional Program Specialist,
National Institute of Corrections. Mr.
Guevara can be reached by calling 800–
995–6429, ext. 6617, or by email at
mguevar@bop.gov. In addition to the
direct reply, all questions and responses
will be posted on NIC’s Web site at
www.nicic.gov for public review (the
names of those submitting questions
will not be posted). The Web site will
be updated regularly and postings will
remain on the Web site until the closing
date of this cooperative agreement
solicitation. Only questions received by
12 p.m. (EDT) on July 13, 2012 will be
posted on the NIC Web site.
SUPPLEMENTARY INFORMATION:
Overview: NIC is revitalizing its
trainer development series with the goal
of helping corrections agencies and
trainers improve staff training and
development. NIC is interested in
updating some of its curricula,
including ‘‘Training Design and
Development,’’ ‘‘Foundation Skills for
Trainers,’’ ‘‘Building Agency Success:
Developing an Effective FTO/OJT
Training Program,’’ and ‘‘Training for
Training Directors.’’ NIC is also
interested in the development of a
model Training for Trainers template
that could be applied broadly, enabling
agencies to train trainers in existing
curricula.
All curricula will follow the
Instructional Theory into Practice (ITIP)
model and will incorporate blended
learning strategies. A copy of the ‘‘ITIP
Toolkit,’’ which may be useful in
helping awardees develop acceptable
curricula, is available on the NIC Web
site at https://nicic.gov/Library/024773.
An essential component of this project
will be the incorporation of current
research on adult learning and
performance. The use of multiple
delivery technologies is required.
Background: NIC has prioritized
capacity building in corrections
agencies for decades. While NIC
frequently relied on traditional
classroom-based training in the past, the
emergence of new technologies and the
E:\FR\FM\05JYN1.SGM
05JYN1
]]>Agencies
[Federal Register Volume 77, Number 129 (Thursday, July 5, 2012)]
[Notices]
[Pages 39737-39741]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-16396]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-363]
Controlled Substances: Proposed Adjustment to the Aggregate
Production Quotas for 2012
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice with request for comments.
-----------------------------------------------------------------------
SUMMARY: This notice proposes to adjust the 2012 aggregate production
quotas for several controlled substances in schedules I and II of the
Controlled Substances Act (CSA).
DATES: Electronic comments must be submitted and written comments must
be postmarked on or before August 6, 2012. Commenters should be aware
that the electronic Federal Docket Management System will not accept
comments after midnight Eastern Time on the last day of the comment
period.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-363'' on all electronic and written correspondence.
DEA encourages all comments be submitted electronically through https://www.regulations.gov using the electronic comment form provided on that
site. An electronic copy of this document is also available at the
https://www.regulations.gov Web site for easy reference. Paper comments
that duplicate the electronic submission are not necessary as all
comments submitted to www.regulations.gov will be posted for public
review and are part of the official docket record. Should you, however,
wish to submit written comments via regular or express mail, they
should be sent to the Drug Enforcement Administration, Attention: DEA
Federal Register Representative/ODL, 8701 Morrissette Drive,
Springfield, VA 22152.
FOR FURTHER INFORMATION CONTACT: John W. Partridge, Chief, Liaison and
Policy Section, Drug Enforcement Administration, 8701 Morrissette
Drive, Springfield, VA 22152, Telephone: (202) 307-4654.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received are considered part of the
public record and made available for public inspection online at https://www.regulations.gov and in the DEA's public docket. Such information
includes personal identifying
[[Page 39738]]
information (such as your name, address, etc.) voluntarily submitted by
the commenter.
If you want to submit personal identifying information (such as
your name, address, etc.) as part of your comment, but do not want it
to be posted online or made available in the public docket, you must
include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first
paragraph of your comment. You must also place all the personal
identifying information you do not want posted online or made available
in the public docket in the first paragraph of your comment and
identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be posted online or made available
in the public docket, you must include the phrase ``CONFIDENTIAL
BUSINESS INFORMATION'' in the first paragraph of your comment. You must
also prominently identify confidential business information to be
redacted within the comment. If a comment has so much confidential
business information that it cannot be effectively redacted, all or
part of that comment may not be posted online or made available in the
public docket.
Personal identifying information and confidential business
information identified and located as set forth above will be redacted,
and the comment, in redacted form, will be posted online and placed in
the DEA's public docket file. Please note that the Freedom of
Information Act applies to all comments received. If you wish to
inspect the agency's public docket file in person by appointment,
please see the FOR FURTHER INFORMATION CONTACT paragraph.
Background
Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney
General establish aggregate production quotas for each basic class of
controlled substance listed in schedules I and II. This responsibility
has been delegated to the Administrator of the DEA by 28 CFR 0.100. The
Administrator, in turn, has redelegated this function to the Deputy
Administrator, pursuant to 28 CFR 0.104. The 2012 established aggregate
production quotas for controlled substances in schedules I and II were
published in the Federal Register (76 FR 78044) on December 15, 2011.
That notice stipulated that, as provided for in 21 CFR 1303.13, all
aggregate production quotas are subject to adjustment.
Analysis for Proposed Revised 2012 Aggregate Production Quotas
DEA now proposes to adjust the established 2012 aggregate
production quotas for some schedule I and II controlled substances. In
proposing the adjustment, DEA has taken into account the criteria that
DEA is required to consider in accordance with 21 CFR 1303.13. DEA
proposes the adjustment of the aggregate production quotas for basic
classes of schedule I and II controlled substances by considering (1)
Changes in demand for the class, changes in the national rate of net
disposal for the class, and changes in the rate of net disposal by the
registrants holding individual manufacturing quotas for the class; (2)
whether any increased demand or changes in the national and/or
individual rates of net disposal are temporary, short term, or long
term; (3) whether any increased demand can be met through existing
inventories, increased individual manufacturing quotas, or increased
importation without increasing the aggregate production quota; (4)
whether any decreased demand will result in excessive inventory
accumulation by all persons registered to handle the class; and (5)
other factors affecting the medical, scientific, research, and
industrial needs of the United States and lawful export requirements,
as the Administrator finds relevant.
In determining whether to propose adjustments to the 2012 aggregate
production quotas, DEA considered updated information obtained from
2011 year-end inventories, 2011 disposition data submitted by quota
applicants, estimates of the medical needs of the United States,
product development, and other information made available to DEA after
the initial aggregate production quotas had been established. The
Deputy Administrator, therefore, proposes to adjust the 2012 aggregate
production quotas for some schedule I and II controlled substances,
expressed in grams of anhydrous acid or base, as follows:
----------------------------------------------------------------------------------------------------------------
Previously established 2012 Proposed adjusted 2012
Basic class quotas quotas
----------------------------------------------------------------------------------------------------------------
Schedule I
----------------------------------------------------------------------------------------------------------------
1-[1-(2-Thienyl)cyclohexyl]piperidine............. 0 g.......................... 5 g.
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole 45 g......................... No Change.
(JWH-200).
1-Butyl-3-(1-naphthoyl)indole (JWH-073)........... 45 g......................... No Change.
1-Methyl-4-phenyl-4-propionoxypiperidine.......... 2 g.......................... No Change.
1-Pentyl-3-(1-naphthoyl)indole (JWH-018).......... 45 g......................... No Change.
2,5-Dimethoxyamphetamine.......................... 2 g.......................... 12 g.
2,5-Dimethoxy-4-ethylamphetamine (DOET)........... 2 g.......................... 12 g.
2,5-Dimethoxy-4-n-propylthiophenethylamine........ 2 g.......................... 12 g.
3-Methylfentanyl.................................. 2 g.......................... No Change.
3-Methylthiofentanyl.............................. 2 g.......................... No Change.
3,4-Methylenedioxyamphetamine (MDA)............... 22 g......................... 30 g.
3,4-Methylenedioxy-N-methylcathinone (methylone).. 8 g.......................... 12 g.
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)...... 15 g......................... 24 g.
3,4-Methylenedioxymethamphetamine (MDMA).......... 22 g......................... 30 g.
3,4-Methylenedioxypyrovalerone (MDPV)............. 8 g.......................... 12 g.
3,4,5-Trimethoxyamphetamine....................... 2 g.......................... 12 g.
4-Bromo-2,5-dimethoxyamphetamine (DOB)............ 2 g.......................... 12 g.
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........ 2 g.......................... 12 g.
4-Methoxyamphetamine.............................. 77 g......................... 88 g.
4-Methylaminorex.................................. 2 g.......................... 12 g.
4-Methyl-2,5-dimethoxyamphetamine (DOM)........... 2 g.......................... 12 g.
4-Methyl-N-methylcathinone (mephedrone)........... 8 g.......................... 12 g.
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- 68 g......................... No Change.
hydroxycyclohexyl]-phenol.
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3- 53 g......................... No Change.
hydroxycyclohexyl]-phenol.
[[Page 39739]]
5-Methoxy-3,4-methylenedioxyamphetamine........... 2 g.......................... 12 g.
5-Methoxy-N,N-diisopropyltryptamine............... 2 g.......................... 12 g.
Acetyl-alpha-methylfentanyl....................... 2 g.......................... No Change.
Acetyldihydrocodeine.............................. 2 g.......................... No Change.
Acetylmethadol.................................... 2 g.......................... No Change.
Allylprodine...................................... 2 g.......................... No Change.
Alphacetylmethadol................................ 2 g.......................... No Change.
Alpha-ethyltryptamine............................. 2 g.......................... 12 g.
Alphameprodine.................................... 2 g.......................... No Change.
Alphamethadol..................................... 2 g.......................... No Change.
Alpha-methylfentanyl.............................. 2 g.......................... No Change.
Alpha-methylthiofentanyl.......................... 2 g.......................... No Change.
Alpha-methyltryptamine (AMT)...................... 2 g.......................... 12 g.
Aminorex.......................................... 2 g.......................... 12 g.
Benzylmorphine.................................... 2 g.......................... No Change.
Betacetylmethadol................................. 2 g.......................... No Change.
Beta-hydroxy-3-methylfentanyl..................... 2 g.......................... No Change.
Beta-hydroxyfentanyl.............................. 2 g.......................... No Change.
Betameprodine..................................... 2 g.......................... No Change.
Betamethadol...................................... 2 g.......................... No Change.
Betaprodine....................................... 2 g.......................... No Change.
Bufotenine........................................ 3 g.......................... No Change.
Cathinone......................................... 4 g.......................... 12 g.
Codeine-N-oxide................................... 602 g........................ No Change.
Diethyltryptamine................................. 2 g.......................... 12 g.
Difenoxin......................................... 50 g......................... No Change.
Dihydromorphine................................... 3,608,000 g.................. No Change.
Dimethyltryptamine................................ 7 g.......................... 18 g.
Gamma-hydroxybutyric acid......................... 47,000,000 g................. No Change.
Heroin............................................ 20 g......................... No Change.
Hydromorphinol.................................... 54 g......................... No Change.
Hydroxypethidine.................................. 2 g.......................... No Change.
Ibogaine.......................................... 5 g.......................... No Change.
Lysergic acid diethylamide (LSD).................. 16 g......................... No Change.
Marihuana......................................... 21,000 g..................... No Change.
Mescaline......................................... 5 g.......................... 13 g.
Methaqualone...................................... 10 g......................... No Change.
Methcathinone..................................... 4 g.......................... 12 g.
Methyldihydromorphine............................. 2 g.......................... No Change.
Morphine-N-oxide.................................. 655 g........................ No Change.
N-Benzylpiperazine................................ 2 g.......................... 12 g.
N,N-Dimethylamphetamine........................... 2 g.......................... 12 g.
N-Ethylamphetamine................................ 2 g.......................... 12 g.
N-Hydroxy-3,4-methylenedioxyamphetamine........... 2 g.......................... 12 g.
Noracymethadol.................................... 2 g.......................... No Change.
Norlevorphanol.................................... 52 g......................... No Change.
Normethadone...................................... 2 g.......................... No Change.
Normorphine....................................... 18 g......................... No Change.
Para-fluorofentanyl............................... 2 g.......................... No Change.
Phenomorphan...................................... 2 g.......................... No Change.
Pholcodine........................................ 2 g.......................... No Change.
Properidine....................................... 2 g.......................... No Change.
Psilocybin........................................ 2 g.......................... No Change.
Psilocyn.......................................... 2 g.......................... No Change.
Tetrahydrocannabinols............................. 393,000 g.................... No Change.
Thiofentanyl...................................... 2 g.......................... No Change.
Tilidine.......................................... 10 g......................... No Change.
Trimeperidine..................................... 2 g.......................... No Change.
----------------------------------------------------------------------------------------------------------------
Schedule II
----------------------------------------------------------------------------------------------------------------
1-Phenylcyclohexylamine........................... 2 g.......................... No Change.
1-Piperdinocyclohexanecarbonitrile................ 2 g.......................... 27 g.
4-Anilino-N-phenethyl-4-piperidine (ANPP)......... 1,800,000 g.................. No Change.
Alfentanil........................................ 15,000 g..................... 19,550 g.
Alphaprodine...................................... 2 g.......................... No Change.
Amobarbital....................................... 40,007 g..................... No Change.
Amphetamine (for conversion)...................... 8,500,000 g..................
Amphetamine (for sale) *.......................... 25,300,000 g................. 33,400,000 g.
----------------------------------------------------------------------------------------------------------------
[[Page 39740]]
* DEA has determined that the revised total quantity to provide for the estimated medical, scientific, research,
and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of
reserve stock is 29,400,000 g. DEA has further determined that an additional 4,000,000 g is necessary to provide
for future research and development needs and unexpected emergencies that could affect market availability.
----------------------------------------------------------------------------------------------------------------
Carfentanil....................................... 0 g.......................... 5 g.
Cocaine........................................... 216,000 g.................... No Change.
Codeine (for conversion).......................... 65,000,000 g................. No Change.
Codeine (for sale)................................ 39,605,000 g................. No Change.
Dextropropoxyphene................................ 7 g.......................... No Change.
Dihydrocodeine.................................... 400,000 g.................... No Change.
Diphenoxylate..................................... 900,000 g.................... No Change.
Ecgonine.......................................... 83,000 g..................... No Change.
Ethylmorphine..................................... 2 g.......................... No Change.
Fentanyl.......................................... 1,428,000 g.................. No Change.
Glutethimide...................................... 2 g.......................... No Change.
Hydrocodone (for sale)............................ 59,000,000 g................. 63,000,000 g.
Hydromorphone..................................... 3,455,000 g.................. 3,628,000 g.
Isomethadone...................................... 4 g.......................... No Change.
Levo-alphacetylmethadol (LAAM).................... 3 g.......................... No Change.
Levomethorphan.................................... 5 g.......................... No Change.
Levorphanol....................................... 3,600 g...................... No Change.
Lisdexamfetamine.................................. 12,000,000 g................. No Change.
Meperidine........................................ 5,500,000 g.................. No Change.
Meperidine Intermediate-A......................... 5 g.......................... No Change.
Meperidine Intermediate-B......................... 9 g.......................... No Change.
Meperidine Intermediate-C......................... 5 g.......................... No Change.
Metazocine........................................ 5 g.......................... No Change.
Methadone (for sale).............................. 20,000,000 g................. No Change.
Methadone Intermediate............................ 26,000,000 g................. No Change.
Methamphetamine................................... 3,130,000 g.................. No Change.
----------------------------------------------------------------------------------------------------------------
[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams
for methamphetamine mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for
sale)]
----------------------------------------------------------------------------------------------------------------
Methylphenidate................................... 56,000,000 g................. No Change.
Morphine (for conversion)......................... 83,000,000 g................. No Change.
Morphine (for sale)............................... 39,000,000 g................. No Change.
Nabilone.......................................... 20,502 g..................... No Change.
Noroxymorphone (for conversion)................... 7,200,000 g.................. No Change.
Noroxymorphone (for sale)......................... 401,000 g.................... 1,981,000 g.
Opium (powder).................................... 63,000 g..................... 73,000 g.
Opium (tincture).................................. 1,000,000 g.................. No Change.
Oripavine......................................... 9,800,000 g.................. 15,300,000 g.
Oxycodone (for conversion)........................ 5,600,000 g.................. No Change.
Oxycodone (for sale).............................. 98,000,000 g................. 98,700,000 g.
Oxymorphone (for conversion)...................... 12,800,000 g................. No Change.
Oxymorphone (for sale)............................ 5,500,000 g.................. No Change.
Pentobarbital..................................... 34,000,000 g................. No Change.
Phenazocine....................................... 5 g.......................... No Change.
Phencyclidine..................................... 24 g......................... No Change.
Phenmetrazine..................................... 2 g.......................... No Change.
Phenylacetone..................................... 16,000,000 g................. No Change.
Racemethorphan.................................... 2 g.......................... No Change.
Remifentanil...................................... 2,500 g...................... No Change.
Secobarbital...................................... 336,002 g.................... No Change.
Sufentanil........................................ 5,000 g...................... No Change.
Tapentadol........................................ 5,400,000 g.................. No Change.
Thebaine.......................................... 116,000,000 g................ No Change.
----------------------------------------------------------------------------------------------------------------
Aggregate production quotas for all other schedule I and II
controlled substances included in 21 CFR 1308.11 and 1308.12 remain at
zero. Pursuant to 21 CFR part 1303, the Deputy Administrator may adjust
the 2012 aggregate production quotas and individual manufacturing
quotas allocated for the year.
Comments
Pursuant to 21 CFR 1303.11 and 1303.13, any interested person may
submit written comments on or objections to these proposed
determinations. Based on comments received in response to this Notice,
the Deputy Administrator may hold a public hearing on one or more
issues raised. In the event the Deputy Administrator decides in his
sole discretion to hold such a hearing, the Deputy Administrator will
publish a notice of any such hearing in the Federal Register. After
consideration of any comments and after a hearing, if one is held, the
Deputy Administrator will publish in the Federal Register a Final
[[Page 39741]]
Order determining any adjustment of the aggregate production quota.
Dated: June 28, 2012.
Michele M. Leonhart,
Administrator.
[FR Doc. 2012-16396 Filed 7-3-12; 8:45 am]
BILLING CODE 4410-09-P
